Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Clarus' Jatenzo Suffers From Off-Label Concerns At US Advisory Committee

Jan 10 2018

• By Derrick Gingery

FDA Advisory Committee Feature image

Related Content

Oral Testosterone Therapy Jatenzo Faces CV, Sampling Tube Issues At Advisory Cmte

Jan 08 2018

Lipocine Testosterone Therapy Faces Safety, Stopping Criteria Concerns At US FDA Advisory Cmte

Jan 09 2018

Clarus’ Oral Testosterone’s Perceived Advantage Becomes Downfall At FDA Panel

Sep 19 2014

Related Companies

Clarus Therapeutics Holdings, Inc.

Lipocine Inc.

Additional Topics

United States Advisory Committees Drug Safety Regulation Drug Approval Standards Gynecology & Urology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window